Drugs / ALVAC-hB7.1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003556 | Jan 1999 → May 2001 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00004032 | Oct 1997 → Apr 2004 | malignant epithelial tumor of ovary | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC-hB7.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003556 ↗ |
| Route | Other | “Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally” NCT00003556 ↗ |